MedTrace Logo

Chongqing Primary Aldosteronism Study

NCT03224312 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2023-09-06

No results posted yet for this study

Summary

We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Conditions

  • Primary Aldosteronism

Interventions

OTHER

no intervention

no intervention

Sponsors & Collaborators

  • Chongqing Medical University

    lead OTHER

Principal Investigators

  • Qifu Li, phD · First Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2027-12-31
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03224312 on ClinicalTrials.gov